Clinical Trials Logo

Prostate Cancer clinical trials

View clinical trials related to Prostate Cancer.

Filter by:

NCT ID: NCT04890314 Enrolling by invitation - Prostate Cancer Clinical Trials

Prostate Cancer - Comparative Outcomes of New Conceptual Paradigms for Treatment

PC-CONCEPT
Start date: May 2021
Phase:
Study type: Observational

This study will use a population-based cohort design to study men with newly diagnosed low- and intermediate-risk prostate cancer at high-volume centers in Southern California (SCa) and New York State (NYS). Complications of contemporary treatments for prostate cancer and quality of life outcomes, such as general health, urinary, sexual, and bowel function, cancer anxiety, and treatment regret will be compared and tracked over the course of this study.

NCT ID: NCT04889742 Recruiting - Prostate Cancer Clinical Trials

Hyperthermia Enhanced Re-irradiation of Loco-regional Recurrent Tumors

HETERERO
Start date: May 10, 2021
Phase: Phase 2
Study type: Interventional

This study investiagates deep-regional or superficial hyperthermia to enhance radiotherapy or chemoradiation in patients that suffer recurrent disease after previous radiotherapy.

NCT ID: NCT04889651 Active, not recruiting - Prostate Cancer Clinical Trials

A Study to Compare the Pharmacokinetics and Safety Between BR9004 and BR9004-1 in Healthy Male Volunteers

Start date: April 15, 2021
Phase: Phase 1
Study type: Interventional

To compare the pharmacokinetics and safety between BR9004 and BR9004-1 in healthy male subjects after a single-dose administration while fasting.

NCT ID: NCT04887935 Not yet recruiting - Prostate Cancer Clinical Trials

Neoadjuvant SGLT2 Inhibition in High-Risk Localized Prostate Cancer

Start date: April 30, 2022
Phase: Phase 1
Study type: Interventional

This is a study of the tolerability and safety of neoadjuvant dapagliflozin for patients with high-risk or very high risk prostatic adenocarcinoma prior to radical prostatectomy. The primary hypothesis is that four weeks of daily dapagliflozin prior to surgery is well-tolerated and safe to use in this patient population.

NCT ID: NCT04886986 Not yet recruiting - Prostate Cancer Clinical Trials

225Ac-J591 Plus 177Lu-PSMA-I&T for mCRPC

Start date: June 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase I/II dose-escalation study of 225Ac-J591 administered together with 177Lu-PSMA-I&T (also known as PNT2002). The two study drugs are 225Ac-J591 and 177Lu-PSMA-I&T. Both drugs are designed to deliver radiation to prostate cancer cells; they are known as radionuclide conjugates (radiation linked to antibodies/molecules that recognize prostate cancer cells). The first phase of the study (phase I) will determine the highest dose of the study drug that can be safely given. The second phase of the study (phase II) will determine the effectiveness of the drug combination in patients with prostate cancer.

NCT ID: NCT04882618 Recruiting - Prostate Cancer Clinical Trials

Use of Indocyanine Green During Pelvic Lymph Node Dissection in Prostate Cancer.

Start date: November 8, 2019
Phase: Phase 4
Study type: Interventional

Standard treatment of local or locally advanced prostate cancer is radical prostatectomy (RRP) surgery. During RRP in certain patients extended lymph node dissection (ELND) is recommended. to detect eligible patients for ELND some nomograms based on clinical factors of them is used. The Briganti nomogram is one of them. If the patient has 7% or more probability on Briganti nomogram, then ELND is recommended. But ELND is complicated surgical procedure and may cause labor lost and cost. It is aimed here to show whether the ICG based fluorescence imaging during laparoscopy may yield higher accuracy to detect metastatic LNs than the conventional ELND?

NCT ID: NCT04879563 Recruiting - Breast Cancer Clinical Trials

Artificial Intelligence Supporting CAncer Patients Across Europe - the ASCAPE Project

ASCAPE
Start date: February 1, 2021
Phase: Phase 2
Study type: Interventional

ASCAPE (Artificial intelligence Supporting CAncer Patients across Europe) is a collaborative research project involving 15 partners from 7 countries, including academic medical centers, SMEs (small and medium-sized enterprises), research centers and universities, aiming to leverage the recent advances in Big Data and AI (Artificial Intelligence) to support cancer patients' Quality of Life (QoL) and health status. Specifically, ASCAPE aims to provide personalized- and AI-based predictions for QoL issues in breast- and prostate cancer patients as well as suggest potential interventions to their physicians. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875351.

NCT ID: NCT04873427 Recruiting - Prostate Cancer Clinical Trials

In Situ Clonal Heterogeneity in Prostatic Diagnostic Biopsies

Start date: April 15, 2021
Phase:
Study type: Observational

This is a retrospective, proof of concept study, which aims at reconstructing the cellular heterogeneity of the tumor in multi-needle diagnostic prostate biopsy as well as any biopsy containing potentially pre-malignant tissue, to study its implications in the clinical history of the disease. For each patient, 2 or more samples will be prepared starting from the FFPE diagnostic material. The biopsy used for assigning the Gleason score will be sequenced, together with two or more of the local peri-proximal biopsies with a higher level of differentiation. Samples will undergo Whole Exome Sequencing with an average coverage of 300x at the Wellcome Sanger Institute (WSI, Hinxton, UK). Sequencing data will be analysed for single nucleotide variants, copy number variants and structural variants by using state-of-the-art data analysis pipeline at WSI. 1. Reconstruction of local PCa heterogeneity in multi-needle diagnostic biopsy with different Gleason scores (6-10) using high-coverage whole exome sequencing (WES) and DP-based clonal analysis; 2. Characterization of the relationships between pathological differentiation (Gleason score) and genomics-measured heterogeneity and malignancy features; 3. Assessment of clinical implications of clonal heterogeneity. The study will include an average of 150 prostatic diagnostic biopsies from a cohort of 20 early metastatic PC patients and 20 non-relapsing/non-metastatic patients with indolent malignant disease.

NCT ID: NCT04869462 Not yet recruiting - Prostate Cancer Clinical Trials

DS Titanium Ligation Clip in Urology (Prostatectomy and Nephrectomy)

DOSTILCU
Start date: June 2021
Phase:
Study type: Observational

Prospective, monocentric, single arm, observational PMCF - Study on the Performance and Safety of Double-Shank Titanium Ligation Clip in Urology (Prostatectomy and Nephrectomy)

NCT ID: NCT04867603 Not yet recruiting - Prostate Cancer Clinical Trials

Digital PET/CT Using [Ga-68]PSMA for Characterization of Prostate Lesions

Start date: August 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate a radioactive diagnostic study drug, which is called Gallium-68 Prostate Specific Membrane Antigen ([Ga-68]PSMA) for characterization of prostate abnormalities.